• Citer

Assessment of estrogenic recruitment before chemotherapy in advanced breast cancer: Preliminary results of a double-blind randomized study of the eortic breast cancer cooperative group

par Paridaens, R. ;Heuson, Jean-Claude ;Julien, Jean Pierre;Veyret, Corinne;van Zijl, Jacobus;Klijn, Jan;Sylvester, Richard J. ;Mignolet, Françoise;EORTC Breast Cancer Cooperative Group,
Référence Journal of steroid biochemistry and molecular biology, 37, 6, page (1109-1113)
Publication Publié, 1990-12

Article révisé par les pairs

• Détails
• Contenu

Résumé :

We investigated whether estrogenic recruitment could enhance the antitumor effect of chemotherapy in 165 patients with advanced breast cancer, presumably sensitive to hormonal treatments (ER + and/or PgR + lesions). The therapeutic regimen consisted of: (a) estrogenic suppression by aminoglutethimide 1 g/day + hydrocortisone 40 mg/day; surgical castration in premenopausal patients only; (b) FAC (5FU 500 mg/m2; ADM 50 mg/m2; CPA 500 mg/m2) for 3 weeks; (c) following randomization, exactly 24h prior to chemotherapy, patients had to take 1 tablet of either placebo (PL) or 50 μg ethinylestradiol (EE2). Tolerance, responses, time to progression and median survival were identical in both groups. Thus, EE2 before chemotherapy did not contribute to the efficacy of this particular therapeutic regimen, which yielded an overall response rate of 64%. We conclude that the validity of the hormonal recruitment concept has not yet been established in clinical practice, so that this approach remains experimental. © 1990.